mRNA Technology Shows Promise for Preventing Muscle Damage from Snakebites
Key Insights
Researchers from the University of Reading and Technical University of Denmark demonstrated that mRNA (search) technology can protect muscle tissue from snake venom-induced damage for the first time.
The treatment uses mRNA (search) wrapped in lipid nanoparticles (search) to teach cells to produce protective antibodies, reducing muscle damage (search) from Bothrops asper (search) venom within 12-24 hours.
Laboratory tests showed the approach reduced key muscle damage (search) markers like creatine kinase (search) and lactate dehydrogenase (search) while preserving healthy muscle structure.
Scientists have successfully adapted COVID-19 (search) vaccine technology to prevent muscle damage (search) from snakebites, potentially offering new hope for the 400,000 people who suffer permanent disabilities from venomous snake encounters each year. The breakthrough research, published in Trends in Biotechnology, represents the first demonstration that mRNA (search) technology can protect muscle tissue from snake venom-induced damage.
The study, led by researchers from the University of Reading and the Technical University of Denmark, focused on the venom of Bothrops asper (search), commonly known as the terciopelo snake, found throughout Central and South America. This species' venom is particularly devastating because it destroys muscle tissue, often leaving victims with permanent disabilities even after receiving standard antivenom (search) treatment.
Novel Approach to Venom Protection
The research team developed a treatment using specific mRNA (search) molecules wrapped in lipid nanoparticles (search) that, when injected into muscle tissue, instruct cells to produce protective antibodies against venom toxins. This approach directly addresses a critical limitation of current antivenoms, which work effectively against toxins in the bloodstream but struggle to reach damaged muscle tissue around bite sites.
"For the first time, we've shown that mRNA (search) technology can protect muscle tissue from snake venom-induced damage. This opens a completely new door for treating snakebites, particularly the local injuries that current antivenoms struggle to prevent," said Professor Sakthi Vaiyapuri, lead author of the study from the University of Reading.
Laboratory and Animal Testing Results
In laboratory tests using human muscle cells, the mRNA (search) treatment demonstrated significant protective effects against both isolated toxins and whole venom. The protective antibodies appeared within 12-24 hours of mRNA injection, providing rapid local protection at the cellular level.
Animal studies using mice showed even more promising results. A single injection of the mRNA (search) treatment protected muscle tissue from toxin-induced injury when administered 48 hours before venom exposure. Treated mice showed substantially lower levels of creatine kinase (search) and lactate dehydrogenase (search)—key enzymes released when muscle tissue is damaged—compared to untreated controls. The treatment also preserved healthy muscle structure, preventing the tissue destruction typically associated with envenomation.
Broader Therapeutic Applications
The technology's potential extends beyond snakebite (search) treatment. Professor Andreas Laustsen, who co-led the study from the Technical University of Denmark, noted: "We tested this treatment on snake venom, but this technology could be even more useful for other conditions where toxins cause harm gradually. For example, it might help block harmful toxins produced by bacteria during infections."
The researchers envision their approach working alongside traditional antivenoms rather than replacing them. While standard treatments handle toxins circulating in the blood, mRNA (search)-delivered antibodies could provide localized protection for tissues that antivenoms cannot reach effectively while also neutralizing toxins in circulation.
Challenges and Future Development
Despite the promising results, several challenges remain before the treatment could reach patients. The current approach targets only a single toxin, while snake venoms typically contain multiple harmful components. Future versions would need to provide broader protection against various venom elements.
"We now need to expand this approach to target multiple venom toxins and solve storage challenges for rural areas, as well as ensure faster production of antibodies in tissues. The potential to reduce disabilities among snakebite (search) victims is significant," Professor Vaiyapuri explained.
Storage presents another significant hurdle, as many snakebite (search) incidents occur in remote areas without reliable refrigeration—a requirement for maintaining mRNA (search) stability. The research team also acknowledges that antibodies take hours to develop, which may limit the treatment's effectiveness in emergency situations.
Global Impact Potential
The development comes at a critical time, as snakebites represent a significant global health burden, killing approximately 140,000 people worldwide annually and causing 400,000 permanent disabilities. The researchers plan to develop treatments targeting additional toxins and investigate whether the approach remains effective when administered after a bite occurs, rather than as a preventive measure.
The team is working to create a mixture of mRNA (search) molecules designed to produce "broadly neutralising antibodies" against multiple venom toxins, potentially offering comprehensive protection against various snake species and their diverse toxic components.